The study, which the company expects to publish later this year, found that enXtra from OmniActive Health Technology quickly increased subjects' mental alertness that sustained for five hours.
OmniActive Health Technologies (Morristown, NJ) announced the results of a randomized, double-blind, placebo-controlled crossover study investigating its caffeine-alternative energy ingredient enXtra. The study, which the company expects to publish later this year found that the ingredient quickly increased mental alertness in subjects that sustained for five hours.
In the study, a total of 62 subjects received a dose of 300 mg/d of enXtra or placebo. Results showed that In addition to mental alertness, scores for attention and focus were greater in the subjects receiving enXtra, with benefits for attention measured as early as 30 minutes.
“These data further demonstrate enXtra’s benefits as a safe, plant-based nootropic ingredient,” said Deshanie Rai, PhD, FACN, vice president, global scientific and regulatory affairs at OmniActive, in a press release. “The findings related to increased mental alertness are consistent with our previously published studies, while these new results additionally demonstrated that individuals who consumed enXtra rated themselves as feeling more energized and less fatigued at the end of the study.”